Skip to content

Study · Randomized controlled trial · n = 60 · 2015

4 results

Role of Serotonin Transporter Changes in Depressive Responses to Sex-Steroid Hormone Manipulation: A Positron Emission Tomography Study.

Frokjaer VG, Pinborg A, Holst KK, Overgaard A, Henningsson S, Heede M, Larsen EC, Jensen PS, Agn M, Nielsen AP, Stenbæk DS, da Cunha-Bang S and 5 more

Show all authors

Lehel S, Siebner HR, Mikkelsen JD, Svarer C, Knudsen GM

Biological psychiatry27 Apr 2015Cited by 105 (Europe PMC)

PMID26004162 (opens in a new tab)DOI10.1016/j.biopsych.2015.04.015 (opens in a new tab)PepBankPUB-26004162
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialSafety outcome

    In healthy women, goserelin increased subclinical depressive symptoms relative to placebo (p = .02).

    In plain wordsIn healthy women, goserelin increased depressive symptoms compared with placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseDepressive symptoms versus placebo
    Study

    n = 60

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg implantAs given in this study (human).

    Source sentences

    Summary
    Sex hormone manipulation with GnRHa significantly triggered subclinical depressive symptoms within-group (p = .003) and relative to placebo (p = .02), which were positively associated with net decreases in estradiol levels (p = .02) from baseline within the GnRHa group.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (mean age 24.3 ± 4.9 years) with regular menstrual cycles between 23 and 35 days.
    Summary · context
    Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo intervention.
    Summary · context
    Sixty women completed follow-up and entered the analyses.
  2. 02HumanNon-randomized trialSafety outcome

    In healthy women, goserelin increased subclinical depressive symptoms within-group (p = .003).

    In plain wordsIn healthy women, depressive symptoms increased after goserelin compared with baseline.

    Peptide
    Goserelin
    Outcome
    IncreaseDepressive symptoms versus baseline
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg implantAs given in this study (human).

    Source sentences

    Summary
    Sex hormone manipulation with GnRHa significantly triggered subclinical depressive symptoms within-group (p = .003) and relative to placebo (p = .02), which were positively associated with net decreases in estradiol levels (p = .02) from baseline within the GnRHa group.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (mean age 24.3 ± 4.9 years) with regular menstrual cycles between 23 and 35 days.
    Summary · context
    Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo intervention.
    Summary · context
    Sixty women completed follow-up and entered the analyses.
  3. 03HumanObservational studyMechanism

    In healthy women, depressive symptoms were associated with increased neocortical SERT binding in the goserelin group relative to placebo (p = .003).

    In plain wordsIn women receiving goserelin, depressive symptoms were linked to increased brain serotonin transporter binding relative to placebo.

    Peptide
    Goserelin
    Outcome
    IncreaseSERT binding and depressive symptoms
    Study

    n = 60

    Comparator
    Placebo
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    3.6 mg implantAs given in this study (human).

    Source sentences

    Summary
    Depressive symptoms were associated with increases in neocortical SERT binding in the GnRHa group relative to placebo (p = .003).
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (mean age 24.3 ± 4.9 years) with regular menstrual cycles between 23 and 35 days.
    Summary · context
    Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo intervention.
    Summary · context
    Sixty women completed follow-up and entered the analyses.
  4. 04HumanObservational studyMechanism

    In women receiving goserelin, depressive symptoms were positively associated with net estradiol decreases (p = .02).

    In plain wordsIn women receiving goserelin, depressive symptoms were linked to decreases in estradiol.

    Peptide
    Goserelin
    Outcome
    Not applicableEstradiol decrease and depressive symptoms
    Study

    n: not reported in source

    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    3.6 mg implantAs given in this study (human).

    Source sentences

    Summary
    Sex hormone manipulation with GnRHa significantly triggered subclinical depressive symptoms within-group (p = .003) and relative to placebo (p = .02), which were positively associated with net decreases in estradiol levels (p = .02) from baseline within the GnRHa group.
    3 context sentences
    Summary · context
    A double-blind, randomized, placebo-controlled study included 63 healthy female volunteers (mean age 24.3 ± 4.9 years) with regular menstrual cycles between 23 and 35 days.
    Summary · context
    Participants were randomized to active (goserelin [GnRHa] 3.6 mg implant) or placebo intervention.
    Summary · context
    Sixty women completed follow-up and entered the analyses.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.